Repatha (evolocumab) economic analysis published in the Journal of the American Medical Association (JAMA) Cardiology.- Amgen
Amgen announced results from a new Repatha (evolocumab) economic analysis published in the Journal of the American Medical Association (JAMA) Cardiology. The study identifies the clinical and economic consequences of treating a population of patients at high-risk of cardiovascular (CV) events and defines the cost-effectiveness of Repatha under various clinical scenarios. The analysis is based on the clinical outcomes from the Repatha outcomes study (FOURIER) in patients with established atherosclerotic cardiovascular disease (ASCVD), such as those who have already had a heart attack or stroke who require additional therapy. The authors include the world's leading cardiologists from UCLA and the Thrombolysis in Myocardial Infarction (TIMI) Study Group, an academic research organization of Brigham & Women's Hospital and an Affiliate of Harvard Medical School.
Repatha was found to be a cost-effective treatment for patients with established ASCVD in the U.S. when the net price is at or below $9,669 per year. While there are no formally established cost-effectiveness thresholds in the U.S., this study utilized thresholds employed by the World Health Organization and the American College of Cardiology/American Heart Association. This estimate of the value-based price range for Repatha is in line with the discount range typical for biologic medicines in the U.S. market when applied to the U.S. list price of Repatha. Repatha delivers even greater value to patients at higher risk as the cost-effectiveness is a function of disease severity and the risk of events.
Comment: Both Repatha and Praluent have a list price of about $14,500 annually, excluding rebates and Amgen has indicated in the past that the net annual price for Repatha is in the range of from $7,700 to $11,200 per year.
Comment: Although in the FOURIER study Repatha met its primary endpoints by adding a 15% reduction in major CV events it did not show a reduction in CV mortality. Amgen has argued that the 26 months duration of the FOURIER trial was not adequate to establish realistic mortality criteria.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins